<DOC>
	<DOCNO>NCT00999947</DOCNO>
	<brief_summary>The purpose trial study genetic phenotypic aspect Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy ( ARVD/C ) , determine impact genetic test clinical practice .</brief_summary>
	<brief_title>Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy</brief_title>
	<detailed_description>Arrhythmogenic right ventricular dysplasia/cardiomyopathy ( ARVD/ARVC ) , inherit myocardial disease predominantly affect right ventricle ( RV ) estimate prevalence general population range 1 5 1000 . It characterize histopathologically fibro-fatty myocardial replacement clinically ventricular arrhythmia may lead sudden death , especially young people athlete . Clinical diagnosis base diagnostic criterion propose International Task Force European Society Cardiology International Society Federation Cardiology ( Task Force 1994 ) , often difficult due broad spectrum clinical feature lond period conceal cardiac expression , delay diagnosis . ARVC/D familial 30 50 % typically transmit autosomal dominant trait variable penetrance . In past year , identification causative mutation plakoglobin ( JUP ) , desmoplakin ( DSP ) , plakophilin-2 ( PKP2 ) , desmoglein-2 ( DSG2 ) , desmocollin-2 ( DSC2 ) foster view ARVC/D disorder desmosome provide new insight pathogenesis . The major recent advance molecular genetics ARVD/C might lead important clinical impact early correct diagnosis patient relatives , potential genotype-phenotype correlation . This key-issue require first clarify optimal molecular strategy , efficiency . Such systematic , detailed comprehensive mutation screen study available . Aim : Study genetic phenotypic aspect Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy ( ARVD/C ) , determine impact genetic test clinical practice . Methods : The study approve Pitié-Salpétriêre Hospital ethical committee ( CPPRB ) write informed consent obtain participate individual , recruit France . A cohort 100 unrelated patient ARVD/C recruit . Clinical evaluation include clinical history , family history , blood sample DNA analysis 12-lead ECG , signal-average ECG , 24-hour ambulatory ECG , transthoracic echocardiography , MRI and/or radionuclide scintigraphy , contrast angiography possible . A clinical diagnosis ARVD/C make accord establish European Society Cardiology / International Society Federation Cardiology Task Force major minor criterion ( Task Force 1994 ) . All available relative propose enrollment study blood sample DNA analysis non invasive cardiac examination , include 12-lead ECG , signal-average ECG , transthoracic echocardiography . Mutational analysis five gene encode desmosomal gene perform index case ( plakoglobin , desmoplakin , plakophilin-2 , desmoglein-2 , desmocollin-2 ) . When mutation identify , available relative analyse . In index case without desmosomal mutation , additional analysis perform accord candidate gene strategy , possible , genome wide approach linkage analysis . Expected result : Determine genetic origin patient ARVD/C whatever familial context . Determine molecular strategy routine genetic testing . Determine impact genetic test diagnostic test patient relative . Determine impact genetics prognostic tool , phenotype-genotype analysis . Determine natural evolution disease relative , penetrance .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
	<criteria>Patient DVDA diagnostic confirm Acceptance even followup Informed consent Impossible understand notice information study Not affiliate social protection</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>genetics</keyword>
	<keyword>mutation screen</keyword>
	<keyword>phenotype-genotype analysis</keyword>
	<keyword>desmosomal gene</keyword>
</DOC>